SG11201400668SA - Wnt compositions and therapeutic uses of such compositions - Google Patents

Wnt compositions and therapeutic uses of such compositions

Info

Publication number
SG11201400668SA
SG11201400668SA SG11201400668SA SG11201400668SA SG11201400668SA SG 11201400668S A SG11201400668S A SG 11201400668SA SG 11201400668S A SG11201400668S A SG 11201400668SA SG 11201400668S A SG11201400668S A SG 11201400668SA SG 11201400668S A SG11201400668S A SG 11201400668SA
Authority
SG
Singapore
Prior art keywords
compositions
wnt
therapeutic uses
therapeutic
wnt compositions
Prior art date
Application number
SG11201400668SA
Other languages
English (en)
Inventor
Tom Tong Lee
Michael J Fitch
Kevin Lai
Monica Bennett
Peter Flynn
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47883976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201400668S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Publication of SG11201400668SA publication Critical patent/SG11201400668SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201400668SA 2011-09-16 2012-09-14 Wnt compositions and therapeutic uses of such compositions SG11201400668SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535913P 2011-09-16 2011-09-16
PCT/US2012/055336 WO2013040309A2 (fr) 2011-09-16 2012-09-14 Compositions wnt et utilisations thérapeutiques desdites compositions

Publications (1)

Publication Number Publication Date
SG11201400668SA true SG11201400668SA (en) 2014-04-28

Family

ID=47883976

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201400668SA SG11201400668SA (en) 2011-09-16 2012-09-14 Wnt compositions and therapeutic uses of such compositions

Country Status (10)

Country Link
US (1) US9873722B2 (fr)
EP (1) EP2748190A4 (fr)
JP (1) JP2014527818A (fr)
KR (1) KR20140062139A (fr)
CN (1) CN103998462A (fr)
AU (2) AU2012308476B2 (fr)
BR (1) BR112014006321A2 (fr)
CA (1) CA2848841A1 (fr)
SG (1) SG11201400668SA (fr)
WO (1) WO2013040309A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459576B (zh) 2009-04-27 2015-04-01 渥太华医院研究所 用于调节干细胞的组合物和方法及其应用
KR20140038358A (ko) * 2011-01-11 2014-03-28 페이트 세러퓨틱스, 인코포레이티드 신규의 Wnt 조성물 및 이러한 조성물의 치료학적 용도
AU2012321103B2 (en) 2011-09-16 2016-05-12 Ottawa Hospital Research Institute Wnt7a compositions and methods of using the same
JP2014527818A (ja) 2011-09-16 2014-10-23 フェイト セラピューティクス，インコーポレイテッド Ｗｎｔ組成物およびそのような組成物の治療的使用
WO2013149337A1 (fr) 2012-04-02 2013-10-10 Hydrogenics Corporation Procédé de démarrage de pile à combustible
MX2016001821A (es) * 2013-10-02 2016-05-24 Univ Leland Stanford Junior Composiciones de wnt y metodos para purificacion.
US20170087188A1 (en) * 2014-03-28 2017-03-30 Ottawa Hospital Research Institute Wnt induced motility and enhanced engraftment of cells
EP2975047A1 (fr) 2014-07-18 2016-01-20 Université de Lausanne Polypeptides Wnt7a et leur utilisation
US10688152B2 (en) 2014-09-22 2020-06-23 Rush University Medical Center Compositions and methods for treating a viral infection
EP3581584B1 (fr) 2014-12-24 2022-03-30 Osaka University Procédé de production de protéine wnt et procédé de stockage de protéine wnt
EP3302465A1 (fr) 2015-06-05 2018-04-11 Vertex Pharmaceuticals Incorporated Triazoles pour le traitement de maladies liées à la démyélinisation
US20180360025A1 (en) * 2015-07-22 2018-12-20 Ramot At Tel-Aviv University Ltd. Article of manufacture and methods for increasing survival of red blood cells
CN108601818A (zh) * 2016-01-28 2018-09-28 小利兰·斯坦福大学托管委员会 Wnt组合物及其无血清合成方法
WO2018106643A1 (fr) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Azoles hétérocycliques pour le traitement de maladies de démyélinisation
WO2018106646A1 (fr) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles pour traiter des maladies démyélinisantes
WO2018106641A1 (fr) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles pour le traitement de maladies démyélinisantes
CN108623692B (zh) * 2017-03-20 2020-11-17 徐寒梅 一种融合蛋白及其制备方法和其应用
GB2581882B (en) * 2017-08-01 2023-03-29 Ankasa Regenerative Therapeutics Inc WNT compositions and methods of process from serum-free culturing conditions
CN111356447B (zh) * 2017-11-16 2023-03-24 艾维塔生物医学公司 细胞膜结合信号传导因子的用途
CN118271444A (zh) * 2017-12-19 2024-07-02 瑟罗泽恩奥普瑞汀公司 Wnt替代分子和其用途
AU2018393074A1 (en) 2017-12-19 2020-07-02 Surrozen Operating, Inc. Anti-frizzled antibodies and methods of use
CN113282524B (zh) * 2021-05-08 2022-08-16 重庆大学 一种缓存分片的配置方法、装置以及存储介质

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544752A (en) 1980-09-22 1985-10-01 Eli Lilly And Company 3-Aryl-5-isothiazolecarboxylic acids and related compounds used to lower uric acid levels
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPH07500961A (ja) 1990-10-01 1995-02-02 ユニバーシティ オブ コネチカット 細胞による選択的内在化を目的としたウイルス及び細胞の標的設定
AU2160992A (en) 1991-06-05 1993-01-12 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Targeted delivery of genes encoding secretory proteins
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
JPH07505773A (ja) 1992-04-03 1995-06-29 ヤング　アレキサンダー　ティー 標的化されたウイルスベクターを用いた遺伝子治療
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
EP0972029A1 (fr) * 1997-03-07 2000-01-19 Human Genome Sciences, Inc. Nouvelles proteines secretees
EP0975781A1 (fr) 1997-04-01 2000-02-02 The General Hospital Corporation Marqueur moleculaire pour cellules souches musculaires
GB9828419D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel compounds
AU2001266787A1 (en) * 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20050130181A1 (en) 2001-05-18 2005-06-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
AU2003269354B2 (en) 2002-09-24 2008-03-06 Neuro Therapeutics Ab Methods for promoting dopaminergic neuronal development by using NG4A-subfamily and Wnt-ligands
WO2004091647A1 (fr) 2003-04-07 2004-10-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions de proteine wnt active
WO2004103394A2 (fr) 2003-05-15 2004-12-02 University Of Chicago Procedes et compositions de regeneration nerveuse
JP4750697B2 (ja) 2003-06-25 2011-08-17 オタワ ヘルス リサーチ インスティテュート 幹細胞の成長及び分化を調節する方法及び組成物
CA2578951A1 (fr) 2004-08-30 2006-03-09 Theregen, Inc. Tissus tridimensionnels de culture et utilisations de ceux-ci
WO2006036175A2 (fr) 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Proteines wnt et detection et traitement du cancer
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
CA2524619A1 (fr) 2005-11-22 2007-05-22 Ottawa Health Research Institute Nouvelles cellules souches, sequences nucleotides et proteines provenant de celles-ci
WO2008109119A2 (fr) 2007-03-05 2008-09-12 The Board Of Trustees Of The Leland Stanford Junior University Compositions de wnt et procédés pour leur utilisation
WO2010014948A1 (fr) 2008-08-01 2010-02-04 The University Of Utah Research Foundation Procédés de traitement utilisant des inhibiteurs de wnt
EP2384116A1 (fr) 2008-12-31 2011-11-09 The Regents of the University of California Compositions wnt2 dominantes négatives et leurs procédés d'utilisation
CN102459576B (zh) * 2009-04-27 2015-04-01 渥太华医院研究所 用于调节干细胞的组合物和方法及其应用
CN102812044A (zh) 2010-01-12 2012-12-05 昂考梅德药品有限公司 Wnt结合剂及其用途
KR20140038358A (ko) 2011-01-11 2014-03-28 페이트 세러퓨틱스, 인코포레이티드 신규의 Wnt 조성물 및 이러한 조성물의 치료학적 용도
JP2014506568A (ja) 2011-01-28 2014-03-17 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ Ｗｎｔ組成物およびその使用方法
AU2012321103B2 (en) 2011-09-16 2016-05-12 Ottawa Hospital Research Institute Wnt7a compositions and methods of using the same
JP2014527818A (ja) 2011-09-16 2014-10-23 フェイト セラピューティクス，インコーポレイテッド Ｗｎｔ組成物およびそのような組成物の治療的使用

Also Published As

Publication number Publication date
AU2012308476A1 (en) 2013-04-18
EP2748190A4 (fr) 2015-01-21
US20150099708A1 (en) 2015-04-09
CA2848841A1 (fr) 2013-03-21
AU2016201547A1 (en) 2016-03-31
EP2748190A2 (fr) 2014-07-02
CN103998462A (zh) 2014-08-20
BR112014006321A2 (pt) 2017-04-11
US9873722B2 (en) 2018-01-23
WO2013040309A3 (fr) 2013-05-10
WO2013040309A2 (fr) 2013-03-21
AU2012308476B2 (en) 2016-04-14
KR20140062139A (ko) 2014-05-22
JP2014527818A (ja) 2014-10-23

Similar Documents

Publication Publication Date Title
SG11201400668SA (en) Wnt compositions and therapeutic uses of such compositions
HK1212729A1 (zh) 核糖核酸調節子組合物和使用方法
EP2675471A4 (fr) Compositions liées à la sérumalbumine humaine et procédés d'utilisation
HK1213798A1 (zh) 治療性化合物和組合物
EP2678018A4 (fr) Combinaison d'inhibiteurs des kinases et utilisations associées
EP2536756A4 (fr) Compositions relatives a l'albumine serique humaine et leurs methodes d'utilisation
EP2584897A4 (fr) Compositions contenant du resvératrol et procédés d'utilisation
HK1193837A1 (zh) 聚脲組合物及其使用方法
EP2603202A4 (fr) Compositions et méthodes pour traiter une tauopathie
EP2836224A4 (fr) Compositions de microbiota et leurs procédés associés
SG10201602752XA (en) Melanin modification compositions and methods of use
EP2663576A4 (fr) Nouvelles compositions de wnt et utilisations thérapeutiques de ces compositions
EP2836218A4 (fr) Compositions prébiotiques et leurs procédés d'utilisation
EP2771030A4 (fr) Compositions et méthodes de traitement de protéinopathies
EP2772483A4 (fr) Compose 4-aminocarbazole et son utilisation
EP2667889A4 (fr) Compositions de wnt et procédés d'utilisation de celles-ci
EP2596112A4 (fr) Compositions d'acétylcystéine et méthodes d'utilisation correspondantes
HK1212251A1 (en) Topical compositions and methods of use
EP2917314A4 (fr) Composition d'oligomère
IL227924A0 (en) Preparations and methods of use for determining a4he
EP2753337A4 (fr) Compositions comprenant des bêta-glucanes et leurs procédés d'utilisation
EP2906041A4 (fr) Compositions et procédés d'utilisation d'un composé de lutte contre l'inappétence
EP2755668A4 (fr) Compositions dérivées de hyr1 et méthodes de traitement les utilisant
HK1209381A1 (en) Preparation of composition comprising gas microbubbles
HK1213151A1 (zh) 葉黃素組合物及使用方法